Macrophages are innate immune cells that are ubiquitously distributed throughout the vertebrate body. Macrophages orchestrate sophisticated processes in development, homeostasis, immunity, and disease 1 . Macrophages residing in tumor tissues are commonly known as tumor-associated macrophages (TAMs) and promote or inhibit tumor growth depending on the activation state 2 . TAMs often predominantly display pro-tumorigenic properties that promote inflammation, angiogenesis, metastasis, and immunosuppression. Nevertheless, TAMs also have the potential to serve as anti-tumor effectors and boost anti-tumor immunity. Thus, targeting TAMs is a promising therapeutic strategy 3 . Antibody-mediated depletion of TAMs has shown promise in preclinical models. Numerous clinical trials are now evaluating macrophage-targeting strategies, often in combination with other immunotherapies 4 . Furthermore, harnessing the anti-tumor functions of macrophages, especially by enhancing M1 polarization and concurrently inhibiting M2 polarization, also represents a promising therapeutic strategy 5 .